Santer, D. M. | bioRxiv Science

bioRxiv2026

Lung Epithelial TLR7 is a Factor in Viral Replication and Pathogenesis

Respiratory virus infections are the leading causes of morbidity and mortality of infants and the elderly worldwide. Currently it is not known how Respiratory Syncytial Virus (RSV) vaccination of infants can cause enhancement of RSV disease, highlighting gaps in our understanding about how viruses like RSV interact with the immune system. Here we address this and show that ERK MAP kinase signaling from Toll-like Receptor-7 (TLR7) detection of RSV and influenza, but not human parainfluenza virus type 3 (HPIV3), infections in bronchial epithelial cells (BECs) drives replication of the viruses. Virus infection is detected by pattern recognition receptors like TLR7 that bind to single stranded RNA (ssRNA) viral replication intermediates in late endosomes. Here we report that TLR7 is expressed in BECs and detects RSV ssRNA, causing ERK MAP kinase signaling. RSV and influenza use this detection and signaling in BECs to drive its replication and infection, a mechanism that counters TLR7s role in antiviral defence. Experimental blockade of TLR7 binding or downstream signalling through ERK MAP kinase decreased RSV and influenza replication, but had no effect on HPIV3. RSV viral loads in mouse and human females were higher compared to males, consistent with higher sex-dependent expression of the TLR7 gene from two copies of the X chromosome in females. In a TLR7 gain of function mouse model there was a significant enhancement of RSV replication and RSV eosinophilic and Th2 disease markers like interleukin-5 (IL-5). In summary, TLR7 is expressed in human lung BECs in the lungs where it acts as a factor in RSV and influenza replication and disease pathogenesis. We propose that this is a major factor in determining the sex-disparity of viral disease.

microbiology↗

bioRxiv2020

Interferons and viruses induce a novel primate-specific isoform dACE2 and not the SARS-CoV-2 receptor ACE2

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which causes COVID-19, utilizes angiotensin-converting enzyme 2 (ACE2) for entry into target cells. ACE2 has been proposed as an interferon-stimulated gene (ISG). Thus, interferon-induced variability in ACE2 expression levels could be important for susceptibility to COVID-19 or its outcomes. Here, we report the discovery of a novel, primate-specific isoform of ACE2, which we designate as deltaACE2 (dACE2). We demonstrate that dACE2, but not ACE2, is an ISG. In vitro, dACE2, which lacks 356 N-terminal amino acids, was non-functional in binding the SARS-CoV-2 spike protein and as a carboxypeptidase. Our results reconcile current knowledge on ACE2 expression and suggest that the ISG-type induction of dACE2 in IFN-high conditions created by treatments, inflammatory tumor microenvironment, or viral co-infections is unlikely to affect the cellular entry of SARS-CoV-2 and promote infection.

genetics↗